Clinical outcome for 49 AML patients according to disease biology
| . | CR, no. (%) . | PR, no. (%) . | NR, no. (%) . | NE, no. (%) . | Overall response, no. (%) . |
|---|---|---|---|---|---|
| Stage of disease | |||||
| Relapse (12) | 11 | 0 | 1 | 0 | 11 (92) |
| Prior allo-SCT (9) | 4 | 1 | 4 | 0 | 5 (55) |
| Primary refractory (16) | 5 | 0 | 10 | 1 | 5 (31) |
| Multirefractory (16) | 1 | 2 | 12 | 1 | 3 (19) |
| MPD/AML (5) | 2 | 0 | 2 | 1 | 2 (40) |
| Total (49) | 19 (39) | 2 (4) | 25 (51) | 3 (6) | 21 (43) |
| Genetics | |||||
| Nonadverse (11) | 8 | 0 | 3 | 0 | 8 (72) |
| Adverse | |||||
| Single (13) | 7 | 2 | 4 | 0 | 9 (50) |
| Complex (18) | 2 | 0 | 14 | 2 | 2 (11) |
| FLT3 mutation (7) | 2 | 0 | 5 | 0 | 2 (29) |
| Total adverse (38) | 11 (29) | 2 (5) | 23 (61) | 2 (5) | 13 (34) |
| . | CR, no. (%) . | PR, no. (%) . | NR, no. (%) . | NE, no. (%) . | Overall response, no. (%) . |
|---|---|---|---|---|---|
| Stage of disease | |||||
| Relapse (12) | 11 | 0 | 1 | 0 | 11 (92) |
| Prior allo-SCT (9) | 4 | 1 | 4 | 0 | 5 (55) |
| Primary refractory (16) | 5 | 0 | 10 | 1 | 5 (31) |
| Multirefractory (16) | 1 | 2 | 12 | 1 | 3 (19) |
| MPD/AML (5) | 2 | 0 | 2 | 1 | 2 (40) |
| Total (49) | 19 (39) | 2 (4) | 25 (51) | 3 (6) | 21 (43) |
| Genetics | |||||
| Nonadverse (11) | 8 | 0 | 3 | 0 | 8 (72) |
| Adverse | |||||
| Single (13) | 7 | 2 | 4 | 0 | 9 (50) |
| Complex (18) | 2 | 0 | 14 | 2 | 2 (11) |
| FLT3 mutation (7) | 2 | 0 | 5 | 0 | 2 (29) |
| Total adverse (38) | 11 (29) | 2 (5) | 23 (61) | 2 (5) | 13 (34) |
PR indicates partial remission; NR, no remission; NE, not evaluable; and MPD, myeloproliferative disease.